Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA): Will There Ever Be an Obesity Drug Blockbuster?

Page 1 of 2

The obesity drug war is about to begin.

Investors are anxiously waiting for the launch of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and Eisai‘s obesity drug Belviq, which will match up with VIVUS, Inc. (NASDAQ:VVUS)‘ Qsymia, which hit pharmacies a few months ago. We’ll also get safety data for Orexigen (NASDAQ:OREX)‘s Contrave later this year, which could put it on the market a few months after that.

But Belviq, Qsymia, and Contrave aren’t the first obesity drugs on the market. We’ve been to this rodeo before. And it wasn’t pretty.

VIVUS, Inc. (NASDAQ:VVUS)A lean history lesson on obesity treatments
Lesson number one: no obesity drug has ever been a blockbuster because of a combination of minimal efficacy combined with safety issues.

Wyeth’s Fen-phen, and Abbott Laboratories (NYSE:ABT)‘ Meridia, were pulled from the market because of side effect issues. Roche’s Xenical is still on the market, but has never racked up monster sales because the drug causes some rather unpleasant side effects. It blocks the uptake of fat, and if patients eat too much fat, let’s just say that it isn’t pretty when it passes out the other end. GlaxoSmithKline plc (ADR) (NYSE:GSK) said it plans to sell Alli, the over-the-counter version of Xexical, presumably because it never reached full potential .

There’s a startlingly large number of American’s that are obese, 78 million adults according to the last count by the CDC . If you charged them all $1,000 per year for an obesity drug, that’s a potential $78 billion market. And yet no drug can get to $1 billion. What’s the problem?

Let me be blunt
There’s one thing some people trying to lose extra weight struggle with: laziness. I speak from experience; I’ve lost a whopping five pounds since I joined my gym more than a year ago. That extra helping of desert is so tempting. So is the snooze alarm.

The characterization is a generalization, of course. There are reasons that people have trouble losing weight other than laziness. But when it comes to drug sales, generalizing is OK. It’s the actions of a large majority that will drive drug sales, not the minority that proves the rule.

Those lazy people are now looking for an easy way to lose weight by taking Belviq and Qsymia, but, unfortunately, there’s no easy way to shed substantial pounds. It takes exercise and dieting to lose weight.

But patients lost weight in clinical trials
Yes they did. The drugs help patients lose weight, but it’s extra weight loss. Almost half of the weight loss seen in the Belviq trials, for instance, could be attributed to lifestyle changes. Patients in the placebo arms of the combined phase 3 trials lost 2.5% of their body weight, compared to 5.8% for patients taking Belviq .

People willing to enter a clinical trial for an unproven drug are likely a lot more motivated to lose weight than the general public. Remember all those side effect issues from other drugs?

And only some of the patients in the trial were actually motivated to lose the weight. A whopping 50% of patients in one of the Belviq trials withdrew before completing one year of the trial.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!